Brian A. Van Tine

机构：Washington University in St. Louis · ORCID：0000-0003-4572-6668

发表论文 495 篇 · 总被引 38946 次 · h-index 65

代表论文

• Safety of the BRD9 heterobifunctional degrader CFT8634 in synovial sarcoma and SMARCB1-null tumors: an open-label, dose-escalation, phase 1 clinical trial (2026 · Communications Medicine)
• Figure S10 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance (2026)
• Figure S5 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance (2026)
• Figure S2 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance (2026)
• Figure S3 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance (2026)
• Figure S11 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance (2026)